Abstract

Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

The title and guidance (section 1) have been updated to reflect the current recommendations. Guidance on strontium ranelate and etidronate have been removed because these drugs are no longer marketed in the UK. NICE has issued up-to-date guidance on bisphosphonates for treating osteoporosis. All other sections are unchanged and refer to all of the drugs originally discussed in 2008.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: we reviewed the evidence and we are updating the recommendations on raloxifine and teriparatide. See the guidance in development page for progress on the update.